Search research articles
Contact Us
Filters
Showing results (141-150 of 155) with videos related to
Page
of 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
Farhad Ravandi, Jorge E Cortes, Daniel Jones, et al.
Crohn'S & Colitis 360
|
March 21, 2022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Quazim A Alayo, Marc Fenster, Osama Altayar, et al.
Blood
|
August 27, 2005
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
Yasuhiro Oki, Hagop M Kantarjian, Xian Zhou, et al.
JAMA Oncology
|
September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
Elias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
Karen W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Cancer
|
October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease
Ghayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
American Journal of Hematology
|
December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor
Nicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
The Lancet. Oncology
|
October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
Elias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Naval Daver, Yanis Boumber, Hagop Kantarjian, et al.
Blood
|
September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza, James A Reeves, Eric J Feldman, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 155) with videos related to
Sort By:
Page
of 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
Farhad Ravandi, Jorge E Cortes, Daniel Jones, et al.
Crohn'S & Colitis 360
|
March 21, 2022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Quazim A Alayo, Marc Fenster, Osama Altayar, et al.
Blood
|
August 27, 2005
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
Yasuhiro Oki, Hagop M Kantarjian, Xian Zhou, et al.
JAMA Oncology
|
September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
Elias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
Karen W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Cancer
|
October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease
Ghayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
American Journal of Hematology
|
December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor
Nicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
The Lancet. Oncology
|
October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
Elias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Naval Daver, Yanis Boumber, Hagop Kantarjian, et al.
Blood
|
September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza, James A Reeves, Eric J Feldman, et al.
Page
of 16